| Attributes | Values |
|---|
| rdf:type
| |
| description
| - article (en)
- ലേഖനം (ml)
- wetenschappelijk artikel (nl)
- article scientifique publié en 2005 (fr)
- im Jahr 2005 veröffentlichter wissenschaftlicher Artikel (de)
- наукова стаття, опублікована в січні 2005 (uk)
|
| publication date
| |
| publication date
| |
| author name string
| |
| author name string
| - Andrew Brown
- Adam Greenstein
- Zunaid Karim
- Alexander Fraser
- Mark A. Quinn
- Clare Brown
- Philip J. O'Connor
- Stephen Jarret
|
| rdfs:label
| - Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (en)
- Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (nl)
|
| skos:prefLabel
| - Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (en)
- Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (nl)
|
| name
| - Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (en)
- Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (nl)
|
| author
| |
| author
| |
| title
| |
| title
| - Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe (en)
|
| page(s)
| |
| page(s)
| |
| instance of
| |
| instance of
| |
| main subject
| |
| main subject
| |
| PubMed ID
| |
| PubMed ID
| |
| PubMed ID
| |
| published in
| |
| published in
| |
| issue
| |
| volume
| |
| issue
| |
| volume
| |
| DOI
| |
| DOI
| |
| DOI
| |
| ResearchGate publication ID
| |
| ResearchGate publication ID
| |
| is about
of | |
| is cites work
of | - Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?
- Cytokines in the pathogenesis of rheumatoid arthritis
- Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
- Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
- Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
- Early start and stop of biologics: has the time come?
- Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study).
- A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.
- Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
- Design of effective immunotherapy for human autoimmunity
- EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
- Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience
- A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
- A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis
- A New-Age for Biologic Therapies: Long-Term Drug-Free Therapy with BiP?
- The changing face of rheumatoid arthritis: sustained remission for all?
- Psychological adjustment to chronic disease
- Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis
- Cells of the synovium in rheumatoid arthritis. Dendritic cells.
- Pathogenesis of rheumatoid arthritis: how early is early?
- Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
- Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence
- Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis
- 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis
- Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
- Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life
- Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
- Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta
- Advances in rheumatology: new targeted therapeutics
- Biologic therapies for inflammatory eye disease
- Depression and health-related quality of life in patients with rheumatoid arthritis.
- Understanding emerging treatment paradigms in rheumatoid arthritis
- Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)